Aquestive Therapeutics Shares Rise After Positive Topline Results for Anaphylm Sublingual Film
By Grace Yoon
Shares of Aquestive Therapeutics were higher after the pharmaceutical company reported positive topline results for its study of Anaphylm sublingual film, which treats allergic reactions.
The stock was up 13% at $4.46 in recent trading, but fell 31% since the start of the year.
The study was conducted in support of the company's submission of its new drug application to the U.S. Food and Drug Administration for the treatment of Type 1 allergic reactions, including anaphylaxis.
Chief Executive Daniel Barber said if anaphylm is approved it has the potential to be the first and only non-invasive, orally delivered epinephrine product for patients at risk of life-threatening allergic reactions.
The company said the new study showed that there was significant improvement across each deficiency identified by the FDA, including difficulties with opening the pouch.
Write to Grace Yoon at grace.yoon@wsj.com
(END) Dow Jones Newswires
August 10, 2026 10:58 ET (14:58 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
6 ETFs To Diversify Away From AI
The Best AI Stocks to Buy Now
United States